Stock AYJ VALNEVA
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Valneva Xetra

Equities

AYJ

FR0004056851

Market Closed - Xetra
Other stock markets
 16:35:38 26/06/2024 BST 		After market 18:16:21
3.372 EUR -1.17% Intraday chart for Valneva 3.392 +0.59%
06-24 Valneva's Chikungunya Vaccine Receives Health Canada's Approval MT
06-24 Valneva rises after Canadian approval for its chikungunya vaccine RE

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
GL
Valneva : 2023 Combined General Meeting – Presentation
PU
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GL
Valneva : Announces Availability of Documentation for its Shareholder Meeting and Provides Corporate Update
PU
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
GL
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GL
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GL
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
AQ
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GL
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
AQ
Valneva : Q1 2024 Financial Results
PU
Valneva : Reports First Quarter 2024 Financial Results and Provides Corporate Updates
PU
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Valneva : Document AMF CP. 2024E960493
PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults
PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VLA Stock
  4. AYJ Stock
  5. News Valneva
  6. Press Releases